Cardiol Therapeutics Inc.

CRDL Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.10 0.05 −4.35%
Market cap
$138.8M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
n/a
Altman Z
3.42
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.89 4.16 4.39 5.55
Net Debt/EBITDA
1.14 4.81 2.85 3.28
Debt/Equity
0.01 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.06) (0.04) (0.05) (0.03)
Book value per Share
0.08 0.15 0.16 0.15
Free Cash Flow
(5.06) (3.55) (5.51) (3.12)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates